Report Subject - Market Access - Page 1

Learn More Pricing and Reimbursement in Neurology

When first line treatments for neurological diseases such as Parkinson's Disease (PD) and Multiple Sclerosis (MS) have been around for years, it's understandable that when something new is approved, people want to try it...

Compare
Learn More Pricing and Reimbursement in Oncology: Payer views

As payer and stakeholder anger mounts, when will the oncology drug price bubble burst? Global cancer drug prices have increased by 10% every year between 1995 and 2013. That level of price inflation is not sustainable...

Compare
Learn More Value-Added Services in Oncology: What motivates payers?

Are your value-added services (VAS) in oncology meeting the needs of payers as well as patients and physicians? Payers are increasingly taking interest in beyond-the-pill services that improve patient adherence,...

Compare
Learn More The Importance of Real World Evidence in Orphan Drugs

Proof of value is an imperative for orphan drug manufacturers: it's the only route to improving patient access and overcoming unmet therapeutic needs for rare conditions. Progress has been made with real world data (RWD)...

Compare
Learn More Market Access Team Structure and Function: Industry Survey 2017

This report gives a unique insight into how US and European market access teams are organised and how they are focusing their time on a day-to-day basis. Market Access Team Structure and Function: Industry Survey 2017...

Compare
Learn More Innovative drugs: Mapping the pricing, reimbursement and HTA landscape

Widespread patient access to innovative new products is being frustrated in non-US markets by Health Technology Assessments (HTA). Between January 2016 and June 2017, 58 innovative medicines were approved and launched in...

Compare
Learn More Value-Added Services in Cardiometabolic Diseases

Pharma's Value-Added Services (VAS) in cardiometabolic disease are not universally appreciated – why? Too often, useful programmes to monitor, educate and support patients are quietly dropped post launch. No wonder...

Compare
Learn More The Future of Market Access in the US

The Future of Market Access in US When it comes to the affordability challenge, have payers and drugmakers reached a stalemate in the US? Pricing wars continue to rage, pharma initiatives are having lacklustre impact,...

Compare
Learn More The Future of Market Access in Europe

The Future of Market Access in Europe The challenges and barriers to market access across Europe continue to be widely debated against the ever-present backdrop of cost-cutting and budgetary pressures. At the same time,...

Compare
Learn More Key Success Factors in Pricing, Reimbursement and Market Access

Key Success Factors in Pricing, Reimbursement and Market Access Novel pricing and reimbursement models are shaping the uptake of medicines. Yet the market access goalposts keep being moved as payer policies, needs and...

Compare
Learn More What do Patients want from Pharma?: The Real Patient-Centric Perspective

What do Patients want from Pharma? How can pharma leverage patient insights to deliver the support they want? Is patient centricity coming of age? The patient voice is becoming increasingly influential and...

Compare
Learn More Biomarkers and Companion Diagnostics - Payer views

Winning Payer Support for Companion Diagnostics & Biomakers How can you positively influence payer attitudes to biomarkers and companion diagnostics (CDx)? Biomarkers and CDx are critical to realising the...

Compare
Learn More Real World Data: Meeting Payer Needs

How to adjust your Real World Data provision to address the real needs of payers Drug costs are spiralling upwards and so too are frustration levels. Payers with stretched budgets are still struggling to make the case...

Compare
Learn More How Payers Want to Work With Pharma

How to effectively engage US and EU payers You’re speaking to payers, but are they listening? Do you really understand their needs and concerns? Is your approach to payer negotiations getting your...

Compare
Learn More Pulling the Data Puzzle Together: Being Payer-Centric

Mapping data with payer needs. How to solve the data puzzle. Everyone is talking about data. What’s being collected; how robust is it; what does it prove; who should be told? From the all-important payer...

Compare
Learn More Charting the Orphan Drug Development Pipeline

Which are the most exciting areas of orphan drug research and where are the best opportunities? Global sales of drugs for orphan indications were estimated to be $114 billion in 2016, with sales forecast to rise to $209...

Compare

Browse by